Estimation of creatinine clearance in end-stage liver disease

David E. Nix, Brian L Erstad, Paul Z. Nakazato, Jeffrey F. Barletta, Kathryn R Matthias, Todd S. Krueger

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

BACKGROUND: Estimation of renal function in patients with end-stage liver disease (ESLD) is complicated by several factors. OBJECTIVE: To develop a practical and relatively inexpensive method for estimating creatinine production and clearance in patients with ESLD. METHODS: Serum creatinine concentrations and urinary excretion of creatinine were measured in 27 patients with moderate-to-severe liver disease with the goal of developing equations to predict creatinine clearance from serum creatinine. Subjects were studied during an initial evaluation for a liver transplant program. Two 24 hour urine specimens were collected along with 3 serum samples over a 2 day evaluation period. Serum and urine creatinine concentrations were determined using both a modified Jaff́ (autoanalyzer) method and an HPLC method. The data were analyzed using nonlinear mixed-effects modeling. RESULTS: Considering both statistical criteria and physiological conventions through allometric scaling theory, creatinine clearance (mL/min) in males can be estimated as (80/serum creatinine) × (actual body weight/70)0.75. For females, the same equation is valid, but the result is multiplied by 0.661. A simplified equation without the exponent is presented, along with equations that are appropriate when an HPLC assay is used for greater specificity. CONCLUSIONS: These equations offer potential for improved estimation of creatinine clearance in patients with liver impairment; however, they need further validation using an independent group of subjects.

Original languageEnglish (US)
Pages (from-to)900-908
Number of pages9
JournalAnnals of Pharmacotherapy
Volume40
Issue number5
DOIs
StatePublished - May 2006

Fingerprint

End Stage Liver Disease
Creatinine
Serum
High Pressure Liquid Chromatography
Urine
Liver
Liver Diseases
Body Weight
Transplants
Kidney

Keywords

  • Assay
  • Creatinine clearance
  • Liver disease
  • Renal function

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Estimation of creatinine clearance in end-stage liver disease. / Nix, David E.; Erstad, Brian L; Nakazato, Paul Z.; Barletta, Jeffrey F.; Matthias, Kathryn R; Krueger, Todd S.

In: Annals of Pharmacotherapy, Vol. 40, No. 5, 05.2006, p. 900-908.

Research output: Contribution to journalArticle

Nix, David E. ; Erstad, Brian L ; Nakazato, Paul Z. ; Barletta, Jeffrey F. ; Matthias, Kathryn R ; Krueger, Todd S. / Estimation of creatinine clearance in end-stage liver disease. In: Annals of Pharmacotherapy. 2006 ; Vol. 40, No. 5. pp. 900-908.
@article{09497d8de1aa4c1eb2b95953f2672d44,
title = "Estimation of creatinine clearance in end-stage liver disease",
abstract = "BACKGROUND: Estimation of renal function in patients with end-stage liver disease (ESLD) is complicated by several factors. OBJECTIVE: To develop a practical and relatively inexpensive method for estimating creatinine production and clearance in patients with ESLD. METHODS: Serum creatinine concentrations and urinary excretion of creatinine were measured in 27 patients with moderate-to-severe liver disease with the goal of developing equations to predict creatinine clearance from serum creatinine. Subjects were studied during an initial evaluation for a liver transplant program. Two 24 hour urine specimens were collected along with 3 serum samples over a 2 day evaluation period. Serum and urine creatinine concentrations were determined using both a modified Jaff́ (autoanalyzer) method and an HPLC method. The data were analyzed using nonlinear mixed-effects modeling. RESULTS: Considering both statistical criteria and physiological conventions through allometric scaling theory, creatinine clearance (mL/min) in males can be estimated as (80/serum creatinine) × (actual body weight/70)0.75. For females, the same equation is valid, but the result is multiplied by 0.661. A simplified equation without the exponent is presented, along with equations that are appropriate when an HPLC assay is used for greater specificity. CONCLUSIONS: These equations offer potential for improved estimation of creatinine clearance in patients with liver impairment; however, they need further validation using an independent group of subjects.",
keywords = "Assay, Creatinine clearance, Liver disease, Renal function",
author = "Nix, {David E.} and Erstad, {Brian L} and Nakazato, {Paul Z.} and Barletta, {Jeffrey F.} and Matthias, {Kathryn R} and Krueger, {Todd S.}",
year = "2006",
month = "5",
doi = "10.1345/aph.1G594",
language = "English (US)",
volume = "40",
pages = "900--908",
journal = "Annals of Pharmacotherapy",
issn = "1060-0280",
publisher = "Harvey Whitney Books Company",
number = "5",

}

TY - JOUR

T1 - Estimation of creatinine clearance in end-stage liver disease

AU - Nix, David E.

AU - Erstad, Brian L

AU - Nakazato, Paul Z.

AU - Barletta, Jeffrey F.

AU - Matthias, Kathryn R

AU - Krueger, Todd S.

PY - 2006/5

Y1 - 2006/5

N2 - BACKGROUND: Estimation of renal function in patients with end-stage liver disease (ESLD) is complicated by several factors. OBJECTIVE: To develop a practical and relatively inexpensive method for estimating creatinine production and clearance in patients with ESLD. METHODS: Serum creatinine concentrations and urinary excretion of creatinine were measured in 27 patients with moderate-to-severe liver disease with the goal of developing equations to predict creatinine clearance from serum creatinine. Subjects were studied during an initial evaluation for a liver transplant program. Two 24 hour urine specimens were collected along with 3 serum samples over a 2 day evaluation period. Serum and urine creatinine concentrations were determined using both a modified Jaff́ (autoanalyzer) method and an HPLC method. The data were analyzed using nonlinear mixed-effects modeling. RESULTS: Considering both statistical criteria and physiological conventions through allometric scaling theory, creatinine clearance (mL/min) in males can be estimated as (80/serum creatinine) × (actual body weight/70)0.75. For females, the same equation is valid, but the result is multiplied by 0.661. A simplified equation without the exponent is presented, along with equations that are appropriate when an HPLC assay is used for greater specificity. CONCLUSIONS: These equations offer potential for improved estimation of creatinine clearance in patients with liver impairment; however, they need further validation using an independent group of subjects.

AB - BACKGROUND: Estimation of renal function in patients with end-stage liver disease (ESLD) is complicated by several factors. OBJECTIVE: To develop a practical and relatively inexpensive method for estimating creatinine production and clearance in patients with ESLD. METHODS: Serum creatinine concentrations and urinary excretion of creatinine were measured in 27 patients with moderate-to-severe liver disease with the goal of developing equations to predict creatinine clearance from serum creatinine. Subjects were studied during an initial evaluation for a liver transplant program. Two 24 hour urine specimens were collected along with 3 serum samples over a 2 day evaluation period. Serum and urine creatinine concentrations were determined using both a modified Jaff́ (autoanalyzer) method and an HPLC method. The data were analyzed using nonlinear mixed-effects modeling. RESULTS: Considering both statistical criteria and physiological conventions through allometric scaling theory, creatinine clearance (mL/min) in males can be estimated as (80/serum creatinine) × (actual body weight/70)0.75. For females, the same equation is valid, but the result is multiplied by 0.661. A simplified equation without the exponent is presented, along with equations that are appropriate when an HPLC assay is used for greater specificity. CONCLUSIONS: These equations offer potential for improved estimation of creatinine clearance in patients with liver impairment; however, they need further validation using an independent group of subjects.

KW - Assay

KW - Creatinine clearance

KW - Liver disease

KW - Renal function

UR - http://www.scopus.com/inward/record.url?scp=33646815273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646815273&partnerID=8YFLogxK

U2 - 10.1345/aph.1G594

DO - 10.1345/aph.1G594

M3 - Article

VL - 40

SP - 900

EP - 908

JO - Annals of Pharmacotherapy

JF - Annals of Pharmacotherapy

SN - 1060-0280

IS - 5

ER -